Ncyte® NHP-C vCardiomyocytes
Ethical Preclinical Safety Research,
From Ncardia
Coming Soon: The First-Ever NHP-Derived Cardiomyocytes
For the first time, cardiomyocytes derived from non-human primates (NHPs) will soon be available for research. Ncyte® NHP-C vCardiomyocytes represent a landmark shift toward more ethical, sustainable, and translational preclinical safety research.
Want to be among the first to experience this groundbreaking product once launched?
Why Ncyte® NHP-C vCardiomyocytes?
Traditional NHP research models involve ethical, logistical, and scientific challenges. Issues can range from unfavorable public scrutiny and regulatory hurdles to limited supply.
Ncyte® NHP-C vCardiomyocytes are a scalable alternative, providing a reliable model for cardiotoxicity screening and drug discovery that:
- Resolves ethical concerns: Reduce reliance on live NHP models
- Improves research consistency: Access a scalable, reproducible cell model
- Overcomes supply shortages: Use a reliable, lab-grown alternative
How can the three main challenges of NHPs impact your research?
Be at the forefront of the next evolution in preclinical safety research. Register now for exclusive updates and a special look at pharmacology data.